Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Dan Stetson"'
Autor:
Veerendra Munugalavadla, Gary de Jesus, Aleksandra Markovets, Qinwen Liu, Oliver Venn, Rafael White, Giulia Fabbri, Paul Labrousse, Dan Stetson, Brian Dougherty, Darren Hodgson, Jill Walker, Anas Younes, Daniel Auclair
Publikováno v:
Cancer Research. 83:3369-3369
Introduction: Minimal or measurable residual disease (MRD) is an emerging independent predictor of progression-free and overall survival in several hematologic diseases. Despite many different methods used in clinical trials, few assays have clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7790fed47f9602e932cbf7c70ba5a8d9
https://doi.org/10.1158/1538-7445.am2023-3369
https://doi.org/10.1158/1538-7445.am2023-3369
Autor:
Ian W. Flinn, Andre Goy, Kathleen A. Burke, Raquel Izumi, Barrett Nuttall, Amelia Raymond, Brandon Willis, Julie M. Vose, J. Elizabeth Pease, Dan Stetson, Brian Dougherty, David Cunningham, Tracy Clevenger, Jean Cheung, Lin Tao, Christopher P. Fox, Anusha Vallurupalli, Elizabeth A. Harrington, Buyue Yang, Stein Schalkwijk, Melanie M. Frigault, Grzegorz S. Nowakowski, Alexander MacDonald, John G. Gribben, Ahmed Hamdy, Mark Roschewski, Larissa S. Carnevalli, Graham P. Collins
Publikováno v:
Leukemialymphoma. 62(11)
In a phase 1b study of acalabrutinib (a covalent Bruton tyrosine kinase (BTK) inhibitor) in combination with vistusertib (a dual mTORC1/2 inhibitor) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), multiple ascending doses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9442e3e6e691178873ad3a2cfee4106
https://pubmed.ncbi.nlm.nih.gov/34269152
https://pubmed.ncbi.nlm.nih.gov/34269152
Publikováno v:
The Journal of Immunology. 196:131.19-131.19
Background The adaptive immune response is critical during the host response to blood stage malaria infection but the cytokine networks important in the development of an appropriate adaptive response are unclear. Type I and Type II gene networks are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19eaf309ff4390c5cc0192b03ff42ad1
https://doi.org/10.4049/jimmunol.196.supp.131.19
https://doi.org/10.4049/jimmunol.196.supp.131.19
Autor:
Hadfield J; James Hadfield, PhD, Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; Chris Abbosh, MD, PhD, Cancer Biomarker Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom, Saga Diagnostics, Lund, Sweden; Darren Hodgson, PhD, Cancer Biomarker Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; Dan Stetson, MS, Translational Medicine, Oncology R&D, AstraZeneca, Waltham, MA., Abbosh C; James Hadfield, PhD, Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; Chris Abbosh, MD, PhD, Cancer Biomarker Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom, Saga Diagnostics, Lund, Sweden; Darren Hodgson, PhD, Cancer Biomarker Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; Dan Stetson, MS, Translational Medicine, Oncology R&D, AstraZeneca, Waltham, MA., Hodgson D; James Hadfield, PhD, Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; Chris Abbosh, MD, PhD, Cancer Biomarker Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom, Saga Diagnostics, Lund, Sweden; Darren Hodgson, PhD, Cancer Biomarker Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; Dan Stetson, MS, Translational Medicine, Oncology R&D, AstraZeneca, Waltham, MA., Stetson D; James Hadfield, PhD, Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; Chris Abbosh, MD, PhD, Cancer Biomarker Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom, Saga Diagnostics, Lund, Sweden; Darren Hodgson, PhD, Cancer Biomarker Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom; Dan Stetson, MS, Translational Medicine, Oncology R&D, AstraZeneca, Waltham, MA.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 11, pp. JCO2401599. Date of Electronic Publication: 2024 Sep 11.